ArandaE., CervantesA., DortaJ., BlancoE., Fernandez MartosC., Cruz HermandezJ.J., CarratoA., Gonzales ManchaR., Garcia CandeJ., Diaz RubioE.: A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).Cancer, 76: 559–563, 1995.
2.
ArdalanB., ChuaL., TianE.M., ReddyR., SridharK., BenedettoP., RichmanS., LegaspiA., WaldmanS., MarcellL.: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma.J. Clin. Oncol., 9: 625–630, 1991.
3.
ArdalanB., SinghG., SilbermanH.: A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.J. Clin. Oncol., 6: 1053–1058, 1988.
4.
BlijhamG., WagenerT., WilsJ., de GreveJ., BusetM., BleibergH., LacaveA., DalmarkM., SelleslagJ., ColletteL., ShamoudT.: Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.J. Clin. Oncol., 14: 2266–2273, 1996.
5.
de GramontA., BossetJ.F., MilanC., RougierP., BoucheO., EtienneP.L., MorvanF., LouvetC., GuillotT., BedenneL.: A prospectively randomized trial comparing 5FU bolus with low dose folinic acid (FUFOLld) and 5FU bolud plus continuous infusion with high dose folinic acid (LV5FU2) for advanced colorectal cancer.Proc. Am. Soc. Clin. Oncol.,14: 194, 1995.
6.
Diaz-RubioE., ArandaE., CampsC., Fernandez-MartosC., CarratoA., AntonA., CervantesA.: A phase II study of weekly 48-hour infusions with high-dose fluorouracil in advanced colorectal cancer: an alternative to biochemical modulation.J. Infusional Chemotherapy, 4: 58–61, 1994.
7.
Diaz-RubioE., ArandaE., MartinM., Gonzalez-ManchaR., Gonzalez-LarribaJ., BarnetoI.: Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer.Eur. J. Cancer., 26: 727–729, 1990.
8.
HaasN.B., HinesJ.B., HudesG.R., JohnstonN., OzolsR.F., O'DwyerP.J.: Phase I trial of 5-fluorouracil by 24-hour infusion weekly.Invest. New Drugs, 11: 181–185, 1993.
9.
HallerD.G., LefkopoulouM., MacdonaldJ.S., MayerR.S.: Some considerations concerning the dose and schedule of 5FU and leucovorin: toxicities of two dose schedules from the intergroup colon adjuvant trial (INT-0089).Adv. Exp. Med. Biol.,339: 51–54, 1993.
10.
JagerE., KleinO., WächterB., MüllerB., BraunU., KnuthA.: Second-line treatment with high-dose 5-fluorouracil and folinic acid in advanced colorectal cancer refractory to standard-dose 5-fluorouracil treatment.Oncology, 52: 470–473, 1995.
11.
KöhneC.H., HiddemannW., SchüllerJ., WeissJ., LohrmannH.P., Schmitz-HubnerU., BodenstainH., SchoberC., WilkeH., GremJ., SchmollH.J.: Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.J. Clin. Oncol., 13: 1201–1208, 1995.
12.
KöhneC.H., SchmollH.J., WilkeH., KäuferC., RauscheckerH., AndreesenR., OhlU., LangeH.J., KlaassenU., WesterhausenM., HiddemannW., SchottG., BadeJ., StrohmeyerG., SchöffskiP., SchubertU., HeckerH., FölshE.: Weekly high dose infusional 5-fluorouracil (FU) plus leucovorin (LV) vs FU plus alpha-interferon (IFN) vs FU plus LV plus IFN in advanced colorecal cancer. Results of a multicentre randomized trial.Proc. Am. Soc. Clin. Oncol.,14: 194, 1995.
13.
KöhneC.H., WilkeH., HeckerH., SchöffskiP., KäuferC., RauscheckerH., AndreesenR., OhlU., LangerH.J., KlaassenU., WesterhausenM., HiddemannW., HennemannB., SchottG., BadeJ., StrohmeyerG., HarstrickA., SchubertU., BokemeyerC., SchmollH.J.: Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).Ann. Oncol.,6: 461–466, 1995.
14.
KöhneC.H., WilkeH., HiddemannW., BokemeyerC., LohrmannH.P., BodensteinH., PreissJ., RauscheckerH., HillH., KäuferC., FischerJ.T., OhlU., UrbanitzD., BalleisenL., SchmollH.J.: Phase II evaluation of 5-fluorouracil plus folinic acid and alpha-2b interferon in metastatic colorectal cancer.Oncology, 1996.
15.
Köhne-WompnerC.H., SchmollH.J., HarstrickA., RustumY.M.: Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.Semin. Oncol., 19: 105–125, 1992.
16.
LeichmanC.G., FlemingT.R., MuggiaF.M., TangenC.M., ArdalanB., DoroshowJ.H., MeyersF.J., HolcombeR.F., WeissG.R., MangalikA.: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.J. Clin. Oncol., 13: 1303–1311, 1995.
17.
LokichJ.J., AhlgrenJ.D., GulloJ.J., PhilipsJ.A., FryerJ.G.: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.J. Clin. Oncol., 7: 425–432, 1989.
18.
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer:evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.J. Clin. Oncol., 10: 896–903, 1992.
19.
O'DwyerP.J., RyanL.M., ValoneF.H., HinesJ.D., ArbuckS.G., WadlerS., HallerD.G., MayerR.J., BensonA.B.: Phase III trial of biochemical modulation of 5-fluorouracil by IV or oral leucovorin or by interferon in advanced colorectal cancer: an ECOG/CALGB phase III trial.Proc. Am. Soc. Clin. Oncol.,15: 207, 1996.
20.
WehH.J., WilkeH.J., DierlammJ., KlaassenU., SiegmundR., IlligerH.J., SchalhornA., KrauserE.D., HilgenfeldU., SteinkeB.: Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).Ann. Oncol., 5: 233–237, 1994.
21.
WilsJ.A.: High-dose fluorouracil: a new perspective in the treatment of colorectal cancer?Semin. Oncol., 19: 126–130, 1992.
